Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017

GlobalData, April 2011, Pages: 108

Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Cancer Pain Therapeutics market. The report identifies the key trends shaping and driving the global Cancer Pain Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Cancer Pain Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Cancer Pain Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Cancer Pain Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Cancer Pain Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Cancer Pain Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Cancer Pain Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Cancer Pain Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Cancer Pain Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Cancer Pain Therapeutics market landscape? – Identify, understand and capitalize.

1
1

1.1 List of Tables
1.2 List of Figures
2 Cancer Pain Therapeutics: Introduction
2.1 Disease Overview
2.2 Etiology and Pathophysiology
2.3 Epidemiology
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 Commonly Used Pain Scales
2.6 Treatment and Management Options
2.6.1 Pharmacologic Management of Cancer Pain:
2.6.2 Non-Opioid Analgesics for Cancer Pain Management
2.6.3 Opioid Drugs for Cancer Pain Management
2.6.4 Adjuvant Drugs
2.7 Pipeline Report Guidance
3 Cancer Pain Therapeutics: Market Characterization
3.1 Cancer Pain Therapeutics Market Size (2005-2010) – Global
3.2 Cancer Pain Therapeutics Market Forecast (2010-2017) – Global
3.3 Cancer Pain Therapeutics Market Size (2005-2010) – The US
3.4 Cancer Pain Therapeutics Market Forecast (2010-2017) – The US
3.5 Cancer Pain Therapeutics Market Size (2005-2010) – France
3.6 Cancer Pain Therapeutics Market Forecast (2010-2017) – France
3.7 Cancer Pain Therapeutics Market Size (2005-2010) – Germany
3.8 Cancer Pain Therapeutics Market Forecast (2010-2017) – Germany
3.9 Cancer Pain Therapeutics Market Size (2005-2010) – Italy
3.10 Cancer Pain Therapeutics Market Forecast (2010-2017) – Italy
3.11 Cancer Pain Therapeutics Market Size (2005-2010) – Spain
3.12 Cancer Pain Therapeutics Market Forecast (2010-2017) – Spain
3.13 Cancer Pain Therapeutics Market Size (2005-2010) – The UK
3.14 Cancer Pain Therapeutics Market Forecast (2010-2017) – The UK
3.15 Cancer Pain Therapeutics Market Size (2005-2010) – Japan
3.16 Cancer Pain Therapeutics Market Forecast (2010-2017) – Japan
3.17 Drivers and Barriers for the Cancer Pain Therapeutics Market
3.17.1 Drivers for the Cancer Pain Therapeutics Market
3.17.2 Barriers for the Cancer Pain Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 Cancer Pain Therapeutics: Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Cancer Pain Therapeutics Market
4.3.1 Actiq
4.3.2 Abstral
4.3.3 Fentora (fentanyl citrate)
4.3.4 Onsolis
4.3.5 Transtec (Buprenorphine)
4.3.6 Lazanda
4.4 Key Takeaway
5 Cancer Pain Therapeutics: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Cancer Pain Therapeutics Pipeline – Pipeline by Phases of Development
5.2.2 Cancer Pain Therapeutics – Regulatory Filed Products
5.2.3 Cancer Pain Therapeutics – Phase III Pipeline
5.2.4 Cancer Pain Therapeutics – Phase II Pipeline
5.2.5 Cancer Pain Therapeutics – Phase I Pipeline
5.2.6 Cancer Pain Market –Pre-Clinical Pipeline
5.2.7 Technology Trends Analytic Framework
5.3 Cancer Pain Therapeutics Market – Clinical Pipeline by Mechanism of Action
5.4 Cancer Pain Therapeutics – Promising Drugs Under Clinical Development
5.5 Molecule Profile for Promising Drugs Under Clinical Development
5.5.1 Ereska (PMI-150, Intranasal Ketamine)
5.5.2 Sativex
5.5.3 Tetrodotoxin (Tectin)
5.6 Key Takeaway
6 Cancer Pain Therapeutics: Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Cancer Pain Therapeutics Clinical Trials
7 Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Cancer Pain Therapeutics: Implications for Future Market Competition
8 Cancer Pain Therapeutics: Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Cephalon, Inc.
8.2.2 Grunenthal GmbH
8.2.3 WEX Pharmaceuticals
8.2.4 Meda AB
8.2.5 ProStrakan Group plc (ProStrakan)
8.2.6 Archimedes Pharma Limited
8.2.7 Shionogi & Co., Ltd.
8.2.8 Hospira, Inc
8.2.9 GW Pharmaceuticals plc
8.2.10 Johnson & Johnson
8.2.11 Other Companies in the Cancer Pain Therapeutics Market
9 Cancer Pain Therapeutics: Licensing and Partnership Deals
10 Cancer Pain Therapeutics: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Acute and Chronic Pain Syndromes
Table 2: Occurrence of Cancer Pain in the Different Tumor Types
Table 3: Non-Opioid Analgesics
Table 4: Opioid Analgesics Used for the Treatment of Cancer Pain
Table 5: Adjuvant Analgesics
Table 6: Cancer Pain Therapeutics Market, Global, Revenue ($m), 2005–2010
Table 7: Cancer Pain Therapeutics Market, Global, Forecast ($m), 2010–2017
Table 8: Cancer Pain Therapeutics Market, The US, Revenue ($m), 2005–2010
Table 9: Cancer Pain Therapeutics Market, The US, Forecasts ($m), 2010–2017
Table 10: Cancer Pain Therapeutics Market, France, Revenue ($m), 2005–2010
Table 11: Cancer Pain Therapeutics Market, France, Forecasts ($m), 2010–2017
Table 12: Cancer Pain Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 13: Cancer Pain Therapeutics Market, Germany, Forecasts ($m), 2010–2017
Table 14: Cancer Pain Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 15: Cancer Pain Therapeutics Market, Italy, Forecasts ($m), 2010–2017
Table 16: Cancer Pain Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 17: Cancer Pain Therapeutics Market, Spain, Forecasts ($m), 2010–2017
Table 18: Cancer Pain Therapeutics Market, The UK, Revenue ($m), 2005–2010
Table 19: Cancer Pain Therapeutics Market, The UK, Forecasts ($m), 2010–2017
Table 20: Cancer Pain Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 21: Cancer Pain Therapeutics Market, Japan, Forecasts ($m), 2010–2017
Table 22: Final Dose of Actiq Following Initial Titration in All Clinical Efficacy and Safety Studies
Table 23: Final Dose of Abstral Following Initial Titration In all Clinical Efficacy and Safety Studies
Table 24: Successful Dose of Fentora Following Initial Titration
Table 25: Dose of Onsolis Following Initial Titration
Table 26: Cancer Pain Therapeutics – Regulatory Filed Products, 2011
Table 27: Cancer Pain Therapeutics – Phase III Pipeline, 2011
Table 28: Cancer Pain Therapeutics – Phase II Pipeline, 2011
Table 29: Cancer Pain Therapeutics – Phase I Pipeline, 2011
Table 30: Cancer Pain Therapeutics –Pre-Clinical Pipeline, 2011
Table 31: Cancer Pain Therapeutics – Most Promising Drugs Under Clinical Development, 2011
Table 32: Cancer Pain Therapeutics – Clinical Trials by Country, 2011
Table 33: Cancer Pain Therapeutics – Clinical Trials by Phase, 2011
Table 34: Cancer Pain Therapeutics – Clinical Trials by Status, 2011
Table 35: Cancer Pain Therapeutics – Prominent Sponsors, 2011
Table 36: Cancer Pain Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 37: Cephalon Inc., Pain Management Pipeline, 2011
Table 38: Cephalon Inc., Deals, 2010–2011
Table 39: Grunenthal GmbH – Pain Management, Pipeline, 2011
Table 40: Grunenthal GmbH – Deals
Table 41: WEX Pharmaceuticals, Pain Management Pipeline, 2011
Table 42: WEX Pharmaceuticals, Cancer Pain Management Pipeline, 2011
Table 43: WEX Pharmaceuticals Inc., Deals , 2010-2011
Table 44: Meda AB Inc., Pain Management Pipeline, 2011
Table 45: Meda AB, Deals, 2010–2011
Table 46: ProStrakan Pain Management Pipeline, 2011
Table 47: ProStrakan, Deals, 2010–2011
Table 48: Archimedes Pharmaceuticals, Pain Management Pipeline, 2011
Table 49: Archimedes Pharmaceuticals, Deals, 2010–2011
Table 50: Shionogi Pharmaceuticals, Pain Management Pipeline, 2011
Table 51: Shionogi Pharmaceuticals, Cancer Pain Management Pipeline, 2011
Table 52: Shionogi, Deals, 2010–2011
Table 53: Hospira, Deals, 2010–2011
Table 54: GW Pharmaceuticals, Pain Management Pipeline, 2011
Table 55: GW Pharmaceuticals, Cancer Pain Management Pipeline, 2011
Table 56: GW Pharmaceuticals, Deals, 2010–2011
Table 57: Johnson & Johnson Pharmaceuticals, Pain Management Pipeline, 2011
Table 58: Johnson & Johnson Pharmaceuticals, Cancer Pain Management Pipeline, 2011
Table 59: Johnson & Johnson, Deals, 2010–2011
Table 60: Cancer Pain Therapeutics Market – Future Players
Table 61: Cancer Pain Therapeutics, Global, Deals

1.2 List of Figures
Figure 1: Breakthrough Pain
Figure 2: Pain Measurement Scale – Numeric Rating Scale
Figure 3: Pain Measurement Scale – Visual Analog Scale
Figure 4: Pain Measurement Scale – Faces Rating Scale
Figure 5: WHO 3–Step Ladder for Cancer Pain Management
Figure 6: Cancer Pain Therapeutics Market, Global, Revenue ($m), 2005–2010
Figure 7: Cancer Pain Therapeutics Market, Global, Forecast ($m), 2010–2017
Figure 8: Cancer Pain Therapeutics Market, The US, Revenue ($m), 2005–2010
Figure 9: Cancer Pain Therapeutics Market, The US, Forecast ($m), 2010–2017
Figure 10: Cancer Pain Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 11: Cancer Pain Therapeutics Market, France, Forecast ($m), 2010–2017
Figure 12: Cancer Pain Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 13: Cancer Pain Therapeutics Market, Germany, Forecast ($m), 2010–2017
Figure 14: Cancer Pain Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 15: Cancer Pain Therapeutics Market, Italy, Forecast ($m), 2010–2017
Figure 16: Cancer Pain Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 17: Cancer Pain Therapeutics Market, Spain, Forecast ($m), 2010–2017
Figure 18: Cancer Pain Therapeutics Market, The UK, Revenue ($m), 2005–2010
Figure 19: Cancer Pain Therapeutics Market, The UK, Forecast ($m), 2010–2017
Figure 20: Cancer Pain Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 21: Cancer Pain Therapeutics Market, Japan, Forecast ($m), 2010–2017
Figure 22: Opportunity and Unmet Need in the Cancer Pain Therapeutics Market
Figure 23: Cancer Pain Therapeutics – Strategic Competitor Assessment, 2010
Figure 24: Cancer Pain Therapeutics – Pipeline by Phase of Development, 2011
Figure 25: Cancer Pain Therapeutics – Technology Trends Analytics Framework, 2011
Figure 26: Cancer Pain Therapeutics – Technology Trends Analytics Framework – Description, 2011
Figure 27: Cancer Pain Therapeutics – Pipeline by Mechanism of Action, 2011
Figure 28: Cancer Pain Therapeutics – Clinical Trials by Country, 2011
Figure 29: Cancer Pain Therapeutics – Clinical Trials by Phase, 2011
Figure 30: Cancer Pain Therapeutics – Clinical Trials by Status, 2011
Figure 31: Cancer Pain Therapeutics – Overall Sponsors, 2011
Figure 32: Cancer Pain Therapeutics – Prominent Sponsors, 2011
Figure 33: Cancer Pain Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 34: Cancer Pain Therapeutics Market, Drivers and Restraints, 2011
Figure 35: Implications for Future Market Competition in the Cancer Pain Market, 2011
Figure 36: Cancer Pain Therapeutics Market – Pipeline by Company, 2011
Figure 37: Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global cancer pain therapeutics market. The report identifies the key trends shaping and driving the global cancer pain therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global cancer pain therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The Cancer Pain Therapeutics Market is Forecast to Show Steady Growth until 2017

GlobalData estimates that the global cancer pain therapeutics market was valued at $2.4 billion in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4% over the next seven years, to reach $3.2 billion by 2017. This steady growth is primarily attributed to the strong pipeline with new first-in-class therapies. The current competitive landscape consists of branded products, generics and off-label drugs. The market remains well-served with the current marketed products, most of which are significantly efficacious in their respective target areas. The pipeline products are expected to provide better benefits, with innovative mechanisms of action. However, the generic availability and physician familiarity with opioids such as immediate-release morphine, NSAIDs and fentanyl will continue to dominate the cancer pain market. Essentially, the global cancer pain market is heading towards a phase of continuous growth, leveraging the current opportunities.

Strong Pipeline is Likely to Result in Steady Growth for the Cancer Pain Market

GlobalData’s analysis shows that the cancer pain therapeutics pipeline is strong, with 23 molecules in various phases of clinical development including 11 first-in-class molecules. Amongst these 11 first-in-class molecules, three molecules are in late stage and the remaining are in the early stages of clinical development. The late stage pipeline molecule Tapentadol (Nucynta ER), an opioid agonist, has been filed for regulatory approval and is expected to launch by 2012. Ereska, Sativex and tetrodotoxin (TTX) are first-in-class products in Phase III, and are expected to be launched by 2015. These products will be responsible for the growth of the cancer pain therapeutics market post-2015. Although the market is adequately served by the current treatment options, the cancer pain therapeutics pipeline will uncover opportunities for the new entrants.

Cephalon, Inc.
Grunenthal GmbH
WEX Pharmaceuticals
Meda AB
ProStrakan Group plc (ProStrakan)
Archimedes Pharma Limited
Shionogi & Co., Ltd.
Hospira, Inc
GW Pharmaceuticals plc
Johnson & Johnson

Customers who bought this item also bought

• Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta
• Pain Therapeutics - Drugs, Markets and Companies
• Pain Management - Global Business Strategic Report
• Acute Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019
• Osteoarthritis Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
• Osteoarthritis (OA) Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019
• Neuropathic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2018
• The Top 50 Developers Of Pain Management Pharmaceuticals Worldwide
• The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights
• Neuropathic Pain: Competing Treatments and Market Entry Considerations